 Oligopeptides
"Oligopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides composed of between two and twelve amino acids.
| Descriptor ID |
D009842
|
| MeSH Number(s) |
D12.644.456
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligopeptides".
Below are MeSH descriptors whose meaning is more specific than "Oligopeptides".
This graph shows the total number of publications written about "Oligopeptides" by people in this website by year, and whether "Oligopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 1 | 3 | 4 | | 1999 | 1 | 4 | 5 | | 2000 | 3 | 3 | 6 | | 2001 | 3 | 3 | 6 | | 2002 | 5 | 1 | 6 | | 2003 | 2 | 4 | 6 | | 2004 | 5 | 3 | 8 | | 2005 | 3 | 3 | 6 | | 2006 | 9 | 3 | 12 | | 2007 | 5 | 5 | 10 | | 2008 | 7 | 1 | 8 | | 2009 | 6 | 7 | 13 | | 2010 | 3 | 2 | 5 | | 2011 | 3 | 8 | 11 | | 2012 | 8 | 2 | 10 | | 2013 | 9 | 6 | 15 | | 2014 | 7 | 3 | 10 | | 2015 | 5 | 3 | 8 | | 2016 | 2 | 4 | 6 | | 2017 | 1 | 1 | 2 | | 2018 | 5 | 2 | 7 | | 2019 | 3 | 3 | 6 | | 2020 | 4 | 0 | 4 | | 2021 | 0 | 1 | 1 | | 2022 | 1 | 4 | 5 | | 2023 | 0 | 1 | 1 | | 2024 | 4 | 2 | 6 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Oligopeptides" by people in Profiles.
-
Sabbah HN, Alder NN, Sparagna GC, Bruce JE, Stauffer BL, Chao LH, Pitceathly RDS, Maack C, Marcinek DJ. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomed Pharmacother. 2025 Jun; 187:118056.
-
Dong S, Banerjee R, Khan AM, Wang M, Wang X, Afghahi A, Afrough A, Janakiram M, Wang B, Cowan AJ, Sperling AS, Anderson LD, Rajkumar SV, Kaur G. Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis. Blood Cancer J. 2025 Mar 28; 15(1):48.
-
Zhou X, Mould DR, Gore L, Bai X, Gupta N. Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis. Clin Pharmacol Ther. 2025 Jun; 117(6):1803-1810.
-
Chang TL, Borelli AN, Cutler AA, Olwin BB, Anseth KS. Myofibers cultured in viscoelastic hydrogels reveal the effects of integrin-binding and mechanosensing on muscle satellite cells. Acta Biomater. 2025 01 15; 192:48-60.
-
Karaa A, Bertini E, Carelli V, Cohen B, Ennes GM, Falk MJ, Goldstein A, Gorman G, Haas R, Hirano M, Klopstock T, Koenig MK, Kornblum C, Lamperti C, Lehman A, Longo N, Molnar MJ, Parikh S, Phan H, Pitceathly RDS, Saneto R, Scaglia F, Servidei S, Tarnopolsky M, Toscano A, Van Hove JLK, Vissing J, Vockley J, Finman JS, Abbruscato A, Brown DA, Sullivan A, Shiffer JA, Mancuso M. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet J Rare Dis. 2024 Nov 21; 19(1):431.
-
Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024 Sep 01; 42(25):3000-3011.
-
Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D. Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leuk Lymphoma. 2024 Sep; 65(9):1362-1365.
-
Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, Major A, Karrison T, Jiang K, Ramsland A, Kubicki T, Jakubowiak AJ. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
-
Kubicki T, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Wr?bel T, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Kruk-Kwapisz D, Derman BA, Major A, Jakubowiak AJ, Dytfeld D. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
-
Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock KM, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine N, Tiffany B, Douglas IS, Levitt J, Busse LW, Ginde AA, Brown SM, Hager DN, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall AJ, DeClercq J, Lavieri R, Joly MM, Orr M, Pulley J, Rice TW, Schildcrout JS, Semler MW, Wang L, Bernard GR, Collins SP. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA. 2023 04 11; 329(14):1170-1182.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|